Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in
diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate
before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI)
scan may help researchers better diagnose glioma in patients with brain tumors.